Research
Hormonal
Preserved mitochondrial function and healthy adipose tissue expansion (via angiogenesis and adiponectin secretion) are key mechanisms that prevent ectopic fat storage and insulin resistance in metabolically healthy obese individuals.
Maintaining healthy adipose tissue function through regular physical activity and avoiding excessive weight gain may help preserve mitochondrial health and prevent the shift from metabolically healthy to unhealthy obesity.
GoodSupportsHIGH confidence
the fundamental feature of MHO seemed to be intact mitochondrial function... preserving healthy adipose tissue with the ability to further expand with proper vascularization and a rate of adipogenesis that keeps pace with the need for additional fat cells is key to preserving elevated adiponectin levels
Why this rating
Supported by animal models (VEGF-A overexpression, mitoNEET) and human twin studies showing preserved mitochondrial pathways.
Source
Metabolically healthy and unhealthy obese – the 2013 <scp>S</scp>tock <scp>C</scp>onference report
Dorit Samocha‐Bonet et al. · Obesity Reviews · 2014
DOI 10.1111/obr.12199
narrative_reviewCited 161×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The metabolically healthy obese (MHO) phenotype is characterized by preserved insulin sensitivity and favorable metabolic markers despite high body fat, primarily driven by reduced visceral and ectopic (liver) fat accumulation and healthy adipose tissue expansion.Good
- Metabolically healthy obese (MHO) is not a stable state; approximately 30% of MHO individuals convert to metabolically unhealthy obese (MUHO) over 5-10 years, primarily due to aging and additional weight gain.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →